Patient P-02316
Therapy response
Improving
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
73%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 No meaningful change — Dietary Support Protocol NP-02
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 71 SC-12 recommended — Supportive Compound SC-12
- Day 72 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 72 Patient accepted — Started SC-12 in the companion
- Day 78 No meaningful change — Supportive Compound SC-12
- Day 80 GI symptom burden −34% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 72.
Primary contributors, last 14 days
- GI instability-5
- Inflammatory activity-3
- Toxicity-3
- Nutritional resilience+2
What helped?
- Dietary Support Protocol NP-02Day 47Result: no meaningful change
- GI Support Protocol GI-04Day 71Result: symptom burden −34%
- Supportive Compound SC-12Day 71Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
88%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 63 and rising
- WearableSleep 5.6 h, below personal baseline
- Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 48
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 40/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 85 bpm
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.7 · butyrate capacity 40/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 50 ms
- Sleep
- 5.4 h
- Steps
- 4,475
- Resting HR
- 87 bpm
Daily log: GI score 63, nutritional resilience 36, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.